Ads
related to: alpha brain when to take medication for cancer disease test tube purpose
Search results
Results From The WOW.Com Content Network
Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. [1] It has the potential to provide highly targeted treatment, especially to microscopic tumour cells.
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [2] [5] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate. [5] [6]
L-α-Glycerophosphorylcholine (alpha-GPC, choline alfoscerate, sn-glycero-3-phosphocholine) is a natural choline compound found in the brain. It is also a parasympathomimetic acetylcholine precursor [ 1 ] which has been investigated for its potential for the treatment of Alzheimer's disease [ 2 ] and other dementias .
The first immunology antibody–drug conjugate (iADC), ABBV-3373, [18] showed an improvement in disease activity in a Phase 2a study of patients with rheumatoid arthritis [19] and a study with the second iADC, ABBV-154 [20] [21] to evaluate adverse events and change in disease activity in participants treated with subcutaneous injection of ABBV ...
The first-in-human tests of a potential treatment are called Phase I studies. Early clinical trials typically enroll a very small number of patients, and the purpose is to identify major safety issues and the maximum tolerated dose, which is the highest dose that does not produce serious or fatal adverse effects. The dose given in these trials ...
It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen. [8] It is on the World Health Organization's List of Essential Medicines. [10] It was approved for medical use in the European Union in August 2007,